Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rivaroxaban + ticagrelor
- Development stage
- Phase 4
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rivaroxaban + ticagrelor is a combination of two oral antithrombotic agents used together for enhanced prevention of thrombotic events, particularly in patients with nonvalvular atrial fibrillation and acute coronary syndrome after percutaneous coronary intervention (PCI)[1][8]. Rivaroxaban is a direct oral anticoagulant that selectively inhibits coagulation factor Xa, thereby blocking the conversion of prothrombin to thrombin and preventing clot formation[6]. Ticagrelor is an oral antiplatelet agent that acts as a reversible antagonist of the P2Y12 adenosine diphosphate receptor on platelets, inhibiting platelet aggregation and reducing the risk of arterial thrombosis[4]. The combination aims to provide both anticoagulant and antiplatelet effects for comprehensive protection against cardiovascular events. However, this regimen carries an increased risk of bleeding and should be used with caution under specialist supervision due to potential drug–drug interactions[2][7].
- Brand names
- Brilinta + Xarelto
- Other names
- ticagrelor plus rivaroxabandual therapy with ticagrelor and rivaroxaban
02
Targets
F10 (Factor Xa)P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on rivaroxaban + ticagrelor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rivaroxaban + ticagrelor.